Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
This study has been terminated.
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00083486
  Purpose

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.


Condition Intervention Phase
Anemia
Drug: epoetin alfa
Phase III

MedlinePlus related topics: Anemia Cancer
Drug Information available for: Epoetin alfa Erythropoietin
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Study Start Date: December 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight >/=99 lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00083486

Locations
United States, Arkansas
Heritage Physician Group-Oncology
Hot Springs, Arkansas, United States, 71913
United States, Georgia
Spalding Oncology Services
Griffin, Georgia, United States, 30224
United States, Illinois
Southern Illinois Hematology
Centralia, Illinois, United States, 62801
United States, Maryland
BioLab Research
Rockville, Maryland, United States, 20852
United States, New York
Slocum-Dickson Medical Group, PC
New Hartford, New York, United States, 13413
United States, North Carolina
NorthEast Urology Research
Concord, North Carolina, United States
United States, Ohio
Mid Ohio Oncology Hematology
Columbus, Ohio, United States, 43213
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
United States, South Carolina
Charleston Cancer Care
Charleston, South Carolina, United States, 29406
Charleston Hematology Oncology
Charleston, South Carolina, United States, 29403
Caroline Cancer Center
Aiken, South Carolina, United States, 29403
United States, Tennessee
Volunteer Research Group
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Study ID Numbers: EPO-CAN-203
Study First Received: May 24, 2004
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00083486  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Epoetin Alfa
Hematologic Diseases
Anemia

Additional relevant MeSH terms:
Hematinics
Therapeutic Uses
Hematologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009